A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Recruiting · NCT03671044 · Registry updated 2025-03-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2025-03-21 | NCT03671044 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Intas Pharmaceuticals, Ltd. | 1 |
| Jina Pharmaceuticals Inc. | 4 |
| Lambda Therapeutic Research Ltd. | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbus Regional Research Institute, LLC | Columbus | United States | 1 |
| Cox Medical Center | Springfield | United States | 3 |
| Gabrail Cancer Center | Canton | United States | 39 |
| Kailash Cancer Hospital & Research Centre | Vadodara | India | 2 |